NCT06179602 Prospective Cohort Study on Thermal Ablation of Malignant Liver Tumors
| NCT ID | NCT06179602 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Leiden University Medical Center |
| Condition | Liver Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2027-12-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2024-01-01 with a primary completion date of 2027-12-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The endpoint of this study is to develop and validate algorithms, using artificial intelligence and machine learning, to optimize patient selection, treatment planning, treatment evaluation and outcome prediction in patients undergoing thermal ablation of a malignant liver tumor. The long-term objective is to establish thermal ablation as the treatment of choice for the vast majority of patients with a primary or secondary liver tumor by development of an accessible workflow that can be widely implemented in different centers performing thermal ablation. Over a time span of at least four years, data will be collected prospectively, encompassing patient information, tumor characteristics, and treatment details. Additionally, pre-, intra-, and post-procedural imaging will be systematically gathered.
Eligibility Criteria
Inclusion Criteria: * 18 years or above * Candidate for percutaneous thermal liver ablation as discussed in a multidisciplinary tumorboard (MDT) * Informed consent Exclusion Criteria: * Patients lacking capacity to give informed consent.
Contact & Investigator
Mark C. Burgmans, MD PhD
PRINCIPAL INVESTIGATOR
Leiden univeristy medical centre
Frequently Asked Questions
Who can join the NCT06179602 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 110 Years, studying Liver Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06179602 currently recruiting?
Yes, NCT06179602 is actively recruiting participants. Contact the research team at c.a.m.verhagen@lumc.nl for enrollment information.
Where is the NCT06179602 trial being conducted?
This trial is being conducted at Leiden, Netherlands.
Who is sponsoring the NCT06179602 clinical trial?
NCT06179602 is sponsored by Leiden University Medical Center. The principal investigator is Mark C. Burgmans, MD PhD at Leiden univeristy medical centre. The trial plans to enroll 1,500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.